ISB News

ISB Builds Digital Platform for COVID-19 Research Study – and Beyond

Covid-19 Platform

View of the responsive recruitment website and electronic consent platform as seen on mobile phone and desktop devices.

ISB is co-leading a one-of-a-kind COVID-19 research study to learn why those infected have drastically different outcomes and to identify targets for medicines and vaccines.

In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. Oftentimes, participants need to enroll at home, rely on a proxy to consent for them due to severity of illness, and/or rely on mobile phones or devices to read and understand study details and agree to participate.

One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.

COVID-19-positive study participants give blood at three different stages during their infection (baseline, acute illness and convalescence). Patients have various levels of symptoms from mild to severe. Patient information is extracted from electronic medical records and multi-omic data is collected on all patients. Given these complexities, a digital platform was needed to manage the collection, analysis, and distribution of de-identified patient data to researchers.

The Health Data Science Lab at ISB was up to the task of converting an otherwise paperwork-heavy process into a digital platform.

“We are working with an experienced, professional team of trial coordinators and physicians at Swedish Medical Center,” said Andrew Magis, director of the Health Data Science Lab. “However, studies such as this one are a lot of work, and hospital staff are busy caring for a lot of sick people right now. We want to use technology where possible to reduce their workload and make the study run more efficiently.”

The digital platform serves many uses, including:

  • Being “mobile friendly” so patients can read and sign the patient consent forms on mobile phones or tablets
  • Integrating with the Swedish Medical Center’s back end for the purpose of annotating and compiling information from a patient’s electronic medical record
  • Supporting the use of mobile phlebotomy for patients who are at home
  • Tracking the progress of each participant throughout the course of the longitudinal study, and
  • Enabling de-identified data to be quickly distributed to ISB researchers and collaborators.

By creating an e-consent platform, it gives already overworked health care workers and hospital staff a digital solution to reduce workload and streamline the trial.

For example, a patient with mild symptoms may have their first blood draw at a Swedish Medical Center location, but after that, a mobile phlebotomist may come to their home to collect their sample. Having technology to support the complex logistical requirements of this study offers great benefits over the traditional paper-based methods.

Magis and his Health Data Science Lab colleagues are building this technology to be scalable, and applicable for other studies ISB will work on with Providence Health and other clinical partners.

“Ultimately we want to create a cloud-based system that interfaces with hospital clinicians, simplifies patient recruitment, blood draw scheduling and sample collection, automates data ingestion and sample biobanking, and enables de-identified multi-omic data to flow to ISB and our collaborators,” said Magis. “It’s an ambitious goal, but one that is possible with the right vision and motivation.”

ISB, Swedish Medical Center, Merck, and several other institutions are collaborating in the COVID-19 Immune Response Study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. Learn more about the research study here.

You can support our groundbreaking COVID-19 research by making a contribution today.

 

Recent Articles

  • Drs. Naeha Subramanian, Leah Rommereim Gilmore, and Ajay Suresh Akhade

    Small, Persistent Increase in the Expression of NOD1 May Promote Cancer Risk

    ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.

  • CRI iAtlas

    CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

    CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.

  • Last-Minute Gift Ideas: 2020 Edition

    Wait, what day is it? What month is it? This year has been a doozy. The pandemic has fundamentally changed our lives, and at times, has made us feel like we’re in a real-life Groundhog Day. Well, if you’ve found yourself in the last-minute shopping scramble, we’re back with a half dozen solid ideas that we hope will make your gift-giving life easier.